ARCHES: OS by high or low disease volume and progression to mHSPC or de novo mHSPC

ARCHES: OS by high or low disease volume and progression to mHSPC or de novo mHSPC

Final OS analysis from ARCHESПодробнее

Final OS analysis from ARCHES

ARCHES: OS in mHSPC who recieved prior ADT and reached low PSA further treated with enzalutamideПодробнее

ARCHES: OS in mHSPC who recieved prior ADT and reached low PSA further treated with enzalutamide

ARCHES post-hoc analyses: efficacy of ENZA + ADT in mHSPC by pattern of metastatic spreadПодробнее

ARCHES post-hoc analyses: efficacy of ENZA + ADT in mHSPC by pattern of metastatic spread

ENZAMET trialПодробнее

ENZAMET trial

ARCHES trial: enzalutamide plus ADT for mHSPCПодробнее

ARCHES trial: enzalutamide plus ADT for mHSPC

ARCHES: radiographic progression in the absence of PSA progression in patients with mHSPCПодробнее

ARCHES: radiographic progression in the absence of PSA progression in patients with mHSPC

ARCHES trial: androgen deprivation therapy with enzalutamide or placebo in mHSPCПодробнее

ARCHES trial: androgen deprivation therapy with enzalutamide or placebo in mHSPC

Enzalutamide + ADT in Men with De Novo mHSPC: The ARCHES TrialПодробнее

Enzalutamide + ADT in Men with De Novo mHSPC: The ARCHES Trial

Genomic characterization of patients with de-novo high-volume mCSPC compared to those withoutПодробнее

Genomic characterization of patients with de-novo high-volume mCSPC compared to those without

Prevalence of DDR alterations in patients with mHSPC enrolled in ARCHESПодробнее

Prevalence of DDR alterations in patients with mHSPC enrolled in ARCHES

mHSPC: Chemo-hormonal Therapy and Treatment IntensificationПодробнее

mHSPC: Chemo-hormonal Therapy and Treatment Intensification

Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Подробнее

Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Update on overall survival in ARCHES trialПодробнее

Update on overall survival in ARCHES trial

ARCHES trialПодробнее

ARCHES trial

ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life Prolonging Therapy in mHSPCПодробнее

ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life Prolonging Therapy in mHSPC

Is There Still a Role for Docetaxel in mHSPC?Подробнее

Is There Still a Role for Docetaxel in mHSPC?

Update on the ARCHES Trial: New Indication for Enzalutamide in mHSPCПодробнее

Update on the ARCHES Trial: New Indication for Enzalutamide in mHSPC

Is there still a role for docetaxel in mHSPC?Подробнее

Is there still a role for docetaxel in mHSPC?

Dr. Stenzl on the Safety Profile of Enzalutamide/ADT in mHSPCПодробнее

Dr. Stenzl on the Safety Profile of Enzalutamide/ADT in mHSPC